BioMarin Pharmaceutical
NASDAQ · BMRN·San Rafael, CA·Large-cap·Approved
Commercial-stage rare disease biopharma with seven approved products including VOXZOGO (vosoritide) for achondroplasia, ROCTAVIAN (gene therapy for hemophilia A), PALYNZIQ for PKU, and several enzyme replacement therapies. Pipeline includes BMN 333 and BMN 351.
Decks (1)
| Title | Occasion | Date | Slides | Source |
|---|---|---|---|---|
| BioMarin Q4 2025 Earnings Presentation | Earnings | February 26, 2026 | 22 |